drug developed janssen pharmaceutica acts potent selective inhibitor enzyme fatty acid amide hydrolase faah described covalently binding slowly reversible selective inhibitor developed treatment anxiety disorders major depressive disorder clinical development progressed far phase ii human trials two studies patients mood disorders registered early trial different faah inhibitor bials bia resulted series severe adverse events including death response janssen announced temporarily suspending dosing two phase ii clinical trials describing decision precautionary measure follows safety issue different drug class janssen emphatic serious adverse events reported clinical trials date suspension remain effect information available bia trials drug article relating nervous system stub help wikipedia expanding